Experimental pill aims to tame deadly inflammation in severe COVID
NCT ID NCT04469621
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested an oral drug called SAR443122 in 68 hospitalized adults with severe COVID-19. The goal was to see if the drug could safely reduce harmful inflammation, measured by a blood marker called CRP. Participants were randomly assigned to receive the drug or a placebo, and researchers tracked their oxygen needs and recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAR443122 (a RIPK1 inhibitor drug taken orally)
What this could lead to
If successful, this could point toward a treatment that calms the dangerous overactive immune response in severe COVID-19, potentially reducing the need for oxygen or ventilator support.
What could go wrong
This is an early phase 1b trial with only 68 participants, so results may not apply broadly. The drug may not improve outcomes or could have side effects not yet seen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 0320001
Caba, 1430, Argentina
-
Investigational Site Number 0760001
São José do Rio Preto, 15090-000, Brazil
-
Investigational Site Number 0760002
São Paulo, 04321-120, Brazil
-
Investigational Site Number 0760003
Porto Alegre, 90035 003, Brazil
-
Investigational Site Number 1520001
Santiago, 750-0691, Chile
-
Investigational Site Number 1520002
Talca, 3460001, Chile
-
Investigational Site Number 1520003
Santiago, 8900085, Chile
-
Investigational Site Number 4840001
Monterrey, 64460, Mexico
-
Investigational Site Number 6430001
Moscow, 111539, Russia
-
Investigational Site Number 6430002
Moscow, 123182, Russia